Type-1 Diabetes Treatment Market Research Report - Global Forecast till 2027

Global Type-1 Diabetes Treatment Market Research Report: By Product (Rapid-Acting Insulin, Short-Acting Insulin, Medium-Acting Insulin, Long-Acting Insulin, Others) and By End User (Hospitals and Clinics, Specialty Centers, Others) – Forecast to 2027

ID: MRFR/HC/6727-HCR | February, 2021 | Region : Global

Market Forecast


Global Type-1 Diabetes Treatment Market is expected to cross USD 9.6 billion by 2025 at a CAGR of 7.9%.


According to the Lancet, type-1 diabetes accounts for 5%–10% of all diabetes cases worldwide. Failure to produce insulin is the cause of this type of diabetes. The onset of the disease may be at a young age or exacerbated by aging and lifestyle, and management requires lifelong medication. Increasing access to medication and rising awareness about the condition are fueling the growth of the market.


Market USP


Lifelong reliance on medication to manage the condition along with the rising prevalence of the disease.


Market Drivers



  • Rising prevalence of type-1 diabetes due to environmental and genetic factors



  • Growing geriatric population, which is susceptible to type-1 diabetes.



  • Increasing prevalence of obesity, which is a contributing factor



  • Rising worldwide spending on healthcare



  • Growing access to medication worldwide



  • Improved diagnostic capabilities ensuring early detection



  • Government support for the treatment of type-1 diabetes


Market Restraints



  • Negative side effects of the medication

  • Stringent approvals process that varies from nation to nation


Segmentation


By Product



  • Rapid-Acting Insulin: The largest and fastest-growing market in this segment. The segment has been further divided into Admelog, Humalog, Novolog, and others.

  • Short-Acting Insulin: Effective for 3–6 hours. Further divided into

  • Medium-Acting Insulin: Effective for 12–18 hours.

  • Long-Acting Insulin: Used for chronic cases and is effective for upwards of 24 hours. The segment has been further divided into Lantus, Levemir, and others.

  • Others: Ultra long-term action insulin and inhaled insulin are covered in this segment.


By End User



  • Hospitals and Clinics: Expected to be the largest and fastest-growing market during the forecast period.

  • Specialty Centers: Catering exclusively to patients suffering from diabetes, these centers are being opened across the globe.

  • Others: Treatment at home and at old age homes are covered in this segment.


By Region



  • Americas

  • Europe

  • Asia-Pacific

  • Middle East & Africa


Regional Analysis



  • Americas: Expected to be the largest market during the forecast period.

  • Europe: A growing market.

  • Asia-Pacific: The fastest-growing market.

  • Middle East & Africa: The smallest market but with a very high number of cases.


Key Players



  • Astellas Pharma (Japan)

  • Eli Lilly (US)

  • Merck (US)

  • Novo Nordisk (Denmark)

  • Sanofi (France)

  • AstraZeneca (UK)

  • Boehringer Ingelheim GmbH (Germany)

  • Novartis (Switzerland)

  • Pfizer Inc. (US)

  • Abbott Laboratories (US)

  • Mannkind Corporation (US)

  • Braun Melsungen AG (Germany)

  • Macrogenics, Inc. (US)

  • DiaVacs, Inc. (US)

  • Biodel, Inc. (US)

Table of Contents

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restrains

4.3 Opportunities

4.4 Challenges

Chapter 5. Market Factor Analysis

5.1 Porters Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

Chapter 6. Global Type-1 Diabetes Treatment Market, by Product

6.1 Introduction

6.2 Rapid-Acting Insulin

6.2.1 Admelog

6.2.2 Humalog

6.2.3 Novolog

6.2.3 Others

6.3 Short-Acting insulin

6.4 Intermediate-Acting insulin

6.5 Long-Acting insulin

6.5.1 Lantus

6.5.2 Levemir

6.5.2 Others

6.5 Others

Chapter 7. Global Type-1 Diabetes Treatment Market, by End User

7.1 Introduction

7.2 Hospitals & Clinics

7.3 Specialty Centers

7.4 Others

Chapter 8. Global Type-1 Diabetes Treatment Market, by Region

8.1 Introduction

8.2 Americas

8.2.1 North America

8.2.1.1 US

8.2.1.2 Canada

8.2.2 Latin America

8.3 Europe

8.3.1 Western Europe

8.3.1.1 Germany

8.3.1.2 France

8.3.1.3 Italy

8.3.1.4 Spain

8.3.1.5 UK

8.3.1.6 Rest of Western Europe

8.3.2 Eastern Europe

8.4 Asia-Pacific

8.4.1 Japan

8.4.2 China

8.4.3 India

8.4.4 Australia

8.4.5 South Korea

8.4.6 Rest of Asia-Pacific

8.5 Middle East & Africa

8.5.1 UAE

8.5.2 Saudi Arabia

8.5.3 Oman

8.5.4 Kuwait

8.5.5 Qatar

8.5.6 Rest of the Middle East & Africa

Chapter 9. Competitive Landscape

9.1 Introduction

9.2 Market Share Analysis

9.3 Key Developments & Strategies

9.3.1 Key Developments

Chapter 10 Company Profiles

10.1 Astellas Pharma

10.1.1. Company Overview

10.1.2. Financial Overview

10.1.3. Products Offered

10.1.4. Key Developments

10.1.5. SWOT Analysis

10.1.6. Key Strategies

10.2 Eli Lilly

10.2.1 Company Overview

10.2.2 Financial Overview

10.2.3 Products Offered

10.2.4 Key Developments

10.2.5 SWOT Analysis

10.2.6 Key Strategies

10.3 Merck

10.3.1 Company Overview

10.3.2 Financial Overview

10.3.3 Products Offered

10.3.4 Key Developments

10.3.5 SWOT Analysis

10.3.6 Key Strategies

10.4 Novo Nordisk

10.4.1 Company Overview

10.4.2 Financial Overview

10.4.3 Products Offered

10.4.4 Key Developments

10.4.5 SWOT Analysis

10.4.6 Key Strategies

10.5 Sanofi

10.5.1 Company Overview

10.5.2 Financial Overview

10.5.3 Products Offered

10.5.4 Key Developments

10.5.5 SWOT Analysis

10.5.6 Key Strategies

10.6 AstraZeneca

10.6.1 Company Overview

10.6.2 Financial Overview

10.6.3 Products Offered

10.6.4 Key Developments

10.6.5 SWOT Analysis

10.6.6 Key Strategies

10.7 Boehringer Ingelheim GmbH

10.7.1 Company Overview

10.7.2 Financial Overview

10.7.3 Products Offered

10.7.4 Key Developments

10.7.5 SWOT Analysis

10.7.6 Key Strategies

10.8 Novartis

10.8.1 Company Overview

10.8.2 Financial Overview

10.8.3 Products Offered

10.8.4 Key Developments

10.8.5 SWOT Analysis

10.8.6 Key Strategies

10.9 Pfizer Inc.

10.9.1 Company Overview

10.9.2 Financial Overview

10.9.3 Products Offered

10.9.4 Key Developments

10.9.5 SWOT Analysis

10.9.6 Key Strategies

10.10 Abbott Laboratories

10.10.1 Company Overview

10.10.2 Financial Overview

10.10.3 Products Offered

10.10.4 Key Developments

10.10.5 SWOT Analysis

10.10.6 Key Strategies

10.11 Mannkind Corporation

10.11.1 Company Overview

10.11.2 Financial Overview

10.11.3 Products Offered

10.11.4 Key Developments

10.11.5 SWOT Analysis

10.11.6 Key Strategies

10.12 B. Braun Melsungen AG

10.12.1 Company Overview

10.12.2 Financial Overview

10.12.3 Products Offered

10.12.4 Key Developments

10.12.5 SWOT Analysis

10.12.6 Key Strategies

10.13 Macrogenics, Inc.

10.13.1 Company Overview

10.13.2 Financial Overview

10.13.3 Products Offered

10.13.4 Key Developments

10.13.5 SWOT Analysis

10.13.6 Key Strategies

10.14 DiaVacs, Inc.

10.14.1 Company Overview

10.14.2 Financial Overview

10.14.3 Products Offered

10.14.4 Key Developments

10.14.5 SWOT Analysis

10.14.6 Key Strategies

10.15 Biodel, Inc.

10.15.1 Company Overview

10.15.2 Financial Overview

10.15.3 Products Offered

10.15.4 Key Developments

10.15.5 SWOT Analysis

10.15.6 Key Strategies

Chapter 11. Appendix

11.1. References

11.2. Related Reports

LIST OF TABLES

Table 1 Global Type-1 Diabetes Treatment Synopsis, 2020-2027

Table 2 Global Type-1 Diabetes Treatment Market Estimates & Forecast, 2020-2027 (USD Million)

Table 3 Global Type-1 Diabetes Treatment Market, by Region 2020-2027 (USD Million)

Table 4 Global Type-1 Diabetes Treatment Market, by Product 2020-2027 (USD Million)

Table 5 Global Type-1 Diabetes Treatment Market, by End User 2020-2027 (USD Million)

Table 6 Americas: Type-1 Diabetes Treatment Market, by Product 2020-2027 (USD Million)

Table 7 Americas: Type-1 Diabetes Treatment Market, by End User 2020-2027 (USD Million)

Table 8 Americas: Type-1 Diabetes Treatment Market, by Region 2020-2027 (USD Million)

Table 9 North America: Type-1 Diabetes Treatment Market, by Product 2020-2027 (USD Million)

Table 10 North America: Type-1 Diabetes Treatment Market, by End User 2020-2027 (USD Million)

Table 11 Latin America: Type-1 Diabetes Treatment Market, by Product 2020-2027 (USD Million)

Table 12 Latin America: Type-1 Diabetes Treatment Market, by End User 2020-2027 (USD Million)

Table 13 Europe: Type-1 Diabetes Treatment Market, by Product 2020-2027 (USD Million)

Table 14 Europe: Type-1 Diabetes Treatment Market, by End User 2020-2027 (USD Million)

Table 15 Europe: Type-1 Diabetes Treatment Market, by Region 2020-2027 (USD Million)

Table 16 Western Europe: Type-1 Diabetes Treatment Market, by Product 2020-2027 (USD Million)

Table 17 Western Europe: Type-1 Diabetes Treatment Market, by End User 2020-2027 (USD Million)

Table 18 Eastern Europe: Type-1 Diabetes Treatment Market, by Product 2020-2027 (USD Million)

Table 19 Eastern Europe: Type-1 Diabetes Treatment Market, by End User 2020-2027 (USD Million)

Table 20 Asia-Pacific: Type-1 Diabetes Treatment Market, by Product 2020-2027 (USD Million)

Table 21 Asia-Pacific: Type-1 Diabetes Treatment Market, by End User 2020-2027 (USD Million)

Table 22 Middle East & Africa: Type-1 Diabetes Treatment Market, by Product 2020-2027 (USD Million)

Table 23 Middle East & Africa: Type-1 Diabetes Treatment Market, by End User 2020-2027 (USD Million)

LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation of the Global Type-1 Diabetes Treatment Market

Figure 3 Market Dynamics for the Global Type-1 Diabetes Treatment Market

Figure 4 Global Type-1 Diabetes Treatment Market Share, by Product, 2020

Figure 5 Global Type-1 Diabetes Treatment Market Share, by End User, 2020

Figure 6 Global Type-1 Diabetes Treatment Market Share, by Region, 2020

Figure 7 Americas: Type-1 Diabetes Treatment Market Share, by Region, 2020

Figure 8 North America: Type-1 Diabetes Treatment Market Share, by Country, 2020

Figure 9 Latin America: Type-1 Diabetes Treatment Market Share, by Country, 2020

Figure 10 Europe: Type-1 Diabetes Treatment Market Share, by Country, 2020

Figure 11 Asia-Pacific: Type-1 Diabetes Treatment Market Share, by Country, 2020

Figure 12 Middle East & Africa: Type-1 Diabetes Treatment Market Share, by Country, 2020

Figure 13 Global Type-1 Diabetes Treatment Market: Company Share Analysis, 2020 (%)

Figure 14 Astellas Pharma: Key Financials

Figure 15 Astellas Pharma: Segmental Revenue

Figure 16 Astellas Pharma: Regional Revenue

Figure 17 Eli Lilly: Key Financials

Figure 18 Eli Lilly: Segmental Revenue

Figure 19 Eli Lilly: Regional Revenue

Figure 20 Merck: Key Financials

Figure 21 Merck: Segmental Revenue

Figure 22 Merck: Regional Revenue

Figure 23 Sanofi: Key Financials

Figure 24 Sanofi: Segmental Revenue

Figure 25 Sanofi: Regional Revenue

Figure 26 Novo Nordisk: Key Financials

Figure 27 Novo Nordisk: Segmental Revenue

Figure 28 Novo Nordisk: Regional Revenue

Figure 29 Biodel, Inc.: Key Financials

Figure 30 Biodel, Inc.: Segmental Revenue

Figure 31 Biodel, Inc.: Regional Revenue

Figure 32 DiaVacs, Inc.: Key Financials

Figure 33 DiaVacs, Inc.: Segmental Revenue

Figure 34 DiaVacs, Inc.: Regional Revenue

Figure 35 Macrogenics, Inc.: Key Financials

Figure 36 Macrogenics, Inc.: Segmental Revenue

Figure 37 Macrogenics, Inc.: Regional Revenue

Figure 38 B. Braun Melsungen AG: Key Financials

Figure 39 B. Braun Melsungen AG: Segmental Revenue

Figure 40 B. Braun Melsungen AG: Regional Revenue

Figure 41 Mannkind Corporation: Key Financials

Figure 42 Mannkind Corporation: Segmental Revenue

Figure 43 Mannkind Corporation: Regional Revenue

Figure 44 Pfizer Inc.: Key Financials

Figure 45 Pfizer Inc.: Segmental Revenue

Figure 46 Pfizer Inc.: Regional Revenue

Figure 47 Abbott Laboratories: Key Financials

Figure 48 Abbott Laboratories: Segmental Revenue

Figure 49 Abbott Laboratories: Regional Revenue

Figure 50 Novartis: Key Financials

Figure 51 Novartis: Segmental Revenue

Figure 52 Novartis: Regional Revenue

Figure 53 Boehringer Ingelheim GmbH: Key Financials

Figure 54 Boehringer Ingelheim GmbH: Segmental Revenue

Figure 55 Boehringer Ingelheim GmbH: Regional Revenue

Figure 56 AstraZeneca: Key Financials

Figure 57 AstraZeneca: Segmental Revenue

Figure 58 AstraZeneca: Regional Revenue




This table of content is tentative and subject to change as the research progresses.

Please Note:  Financial details of company cannot be provided if the information of the company is not available in public domain and or reliable source.

Type 1 Diabetes Treatment Market